6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Increased O
Mortality B-NonOSE_AE
, O
Myocardial B-OSE_Labeled_AE
Infarction I-OSE_Labeled_AE
, O
Stroke B-OSE_Labeled_AE
, O
and O
Thromboembolism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Increased O
Mortality B-NonOSE_AE
and/or O
Increased O
Risk O
of O
Tumor B-OSE_Labeled_AE
Progression I-OSE_Labeled_AE
or O
Recurrence O
in O
Patients O
with O
Cancer B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
PRCA B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serious O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Severe O
Cutaneous B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Patients O
with O
CKD B-Not_AE_Candidate
: O
Adverse O
reactions O
in O
> O
= O
10 O
% O
of O
Aranesp-treated O
patients O
in O
clinical O
studies O
were O
hypertension B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
procedural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
( O
6.1 O
) O
. O

* O
Patients O
with O
Cancer B-Not_AE_Candidate
Receiving O
Chemotherapy O
: O
Adverse O
reactions O
in O
> O
= O
1 O
% O
of O
Aranesp-treated O
patients O
in O
clinical O
studies O
were O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
and O
thrombovascular B-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
6.1 O
) O
. O

EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Medical O
Information O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
other O
drugs O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Patients O
with O
Chronic O
Kidney O
Disease O
Adult O
Patients O
Adverse O
reactions O
were O
determined O
based O
on O
pooled O
data O
from O
5 O
randomized O
, O
active-controlled O
studies O
of O
Aranesp O
with O
a O
total O
of O
1357 O
patients O
( O
Aranesp O
766 O
, O
epoetin O
alfa O
591 O
) O
. O

The O
median O
duration O
of O
exposure O
for O
patients O
receiving O
Aranesp O
was O
340 O
days O
, O
with O
580 O
patients O
exposed O
for O
greater O
than O
6 O
months O
and O
360 O
patients O
exposed O
for O
greater O
than O
1 O
year O
. O

The O
median O
( O
25th O
, O
75th O
percentiles O
) O
weight-adjusted O
dose O
of O
Aranesp O
was O
0.50 O
mcg/kg O
( O
0.32 O
, O
0.81 O
) O
. O

The O
median O
( O
range O
) O
age O
for O
patients O
administered O
Aranesp O
was O
62 O
years O
( O
18 O
to O
88 O
) O
. O

In O
the O
Aranesp O
group O
, O
55 O
% O
were O
male O
, O
72 O
% O
were O
white O
, O
83 O
% O
were O
receiving O
dialysis O
, O
and O
17 O
% O
were O
not O
receiving O
dialysis O
. O

Table O
5 O
lists O
adverse O
reactions O
occurring O
in O
> O
= O
5 O
% O
of O
patients O
treated O
with O
Aranesp O
. O

Table O
5 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
= O
5 O
% O
of O
Patients O
with O
CKD O
Adverse O
Reaction O
Patients O
Treated O
w O
ith O
Aranesp O
( O
n O
= O
766 O
) O
Hypertension B-OSE_Labeled_AE
31 O
% O
Dyspnea B-OSE_Labeled_AE
17 O
% O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
17 O
% O
Cough B-OSE_Labeled_AE
12 O
% O
Procedural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
10 O
% O
Angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
8 O
% O
Vascular B-OSE_Labeled_AE
access I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
8 O
% O
Fluid B-OSE_Labeled_AE
overload I-OSE_Labeled_AE
7 O
% O
Rash B-OSE_Labeled_AE
/ O
Erythema B-OSE_Labeled_AE
5 O
% O
Arteriovenous B-OSE_Labeled_AE
graft I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
5 O
% O
Rates O
of O
adverse O
reactions O
with O
Aranesp O
therapy O
were O
similar O
to O
those O
observed O
with O
other O
recombinant O
erythropoietins O
in O
these O
studies O
. O

Pediatric O
Patients O
Adverse O
reactions O
were O
determined O
based O
on O
pooled O
data O
from O
2 O
randomized O
, O
controlled O
trials O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

In O
one O
study O
, O
Aranesp O
was O
administered O
to O
81 O
pediatric O
patients O
with O
CKD B-Not_AE_Candidate
who O
had O
stable O
hemoglobin O
concentrations O
while O
previously O
receiving O
epoetin O
alfa O
. O

In O
a O
second O
study O
, O
Aranesp O
was O
administered O
to O
114 O
anemic O
pediatric O
patients O
with O
CKD B-Not_AE_Candidate
receiving O
or O
not O
receiving O
dialysis O
for O
initial O
treatment O
of O
anemia B-Not_AE_Candidate
. O

In O
these O
studies O
, O
the O
most O
frequently O
reported O
serious O
adverse O
reactions O
with O
Aranesp O
were O
hypertension B-OSE_Labeled_AE
and O
convulsions B-OSE_Labeled_AE
. O

The O
most O
commonly O
reported O
adverse O
reactions O
were O
hypertension B-OSE_Labeled_AE
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
and O
convulsions B-OSE_Labeled_AE
. O

Aranesp O
administration O
was O
discontinued O
because O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
in O
2 O
patients O
and O
hypertension B-OSE_Labeled_AE
in O
3 O
patients O
. O

Patients O
with O
Cancer O
Receiving O
Chemotherapy O
Adverse O
reactions O
were O
based O
on O
data O
from O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
of O
Aranesp O
in O
597 O
patients O
( O
Aranesp O
301 O
, O
placebo O
296 O
) O
with O
extensive O
stage O
small B-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( I-Not_AE_Candidate
SCLC I-Not_AE_Candidate
) O
receiving O
platinum-based O
chemotherapy O
. O

All O
patients O
were O
white O
, O
64 O
% O
were O
male O
, O
and O
the O
median O
age O
was O
61 O
years O
( O
range O
: O
28 O
to O
82 O
years O
) O
; O
25 O
% O
of O
the O
study O
population O
were O
from O
North O
America O
, O
Western O
Europe O
, O
and O
Australia O
. O

Patients O
received O
Aranesp O
at O
a O
dose O
of O
300 O
mcg O
or O
placebo O
weekly O
for O
4 O
weeks O
then O
every O
3 O
weeks O
for O
a O
total O
of O
24 O
weeks O
, O
and O
the O
median O
duration O
of O
exposure O
was O
19 O
weeks O
( O
range O
: O
1 O
to O
26 O
weeks O
) O
. O

Adverse O
reactions O
were O
also O
based O
on O
data O
from O
7 O
randomized O
, O
double-blind O
, O
placebo-controlled O
studies O
, O
including O
the O
SCLC O
study O
described O
above O
, O
that O
enrolled O
2112 O
patients O
( O
Aranesp O
1203 O
, O
placebo O
909 O
) O
with O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
myeloid I-Not_AE_Candidate
malignancies I-Not_AE_Candidate
. O

Most O
patients O
were O
white O
( O
95 O
% O
) O
, O
male O
( O
52 O
% O
) O
, O
and O
the O
median O
age O
was O
63 O
years O
( O
range O
: O
18 O
to O
91 O
years O
) O
; O
73 O
% O
of O
the O
study O
population O
were O
from O
North O
America O
, O
Western O
Europe O
, O
and O
Australia O
. O

Dosing O
and O
schedules O
varied O
by O
study O
from O
once O
weekly O
to O
once O
every O
4 O
weeks O
, O
and O
the O
median O
duration O
of O
exposure O
was O
12 O
weeks O
( O
range O
: O
1 O
to O
27 O
weeks O
) O
. O

Table O
6 O
. O

Thrombovascular O
Adverse O
Reactions O
in O
Patients O
Receiving O
Chemotherapy O
SCLC O
Study O
All O
Placebo O
- O
controlled O
Studies O
Adverse O
Reaction O
Aranesp O
( O
n O
= O
301 O
) O
Placebo O
( O
n O
= O
296 O
) O
Aranesp O
( O
n O
= O
1203 O
) O
Placebo O
( O
n O
= O
909 O
) O
Thromboembolic B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
, O
n O
( O
% O
) O
24 O
( O
8.0 O
% O
) O
13 O
( O
4.4 O
% O
) O
73 O
( O
6.1 O
% O
) O
37 O
( O
4.1 O
% O
) O
Arterial O
10 O
( O
3.3 O
% O
) O
3 O
( O
1.0 O
% O
) O
15 O
( O
1.2 O
% O
) O
5 O
( O
0.6 O
% O
) O
Myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
5 O
( O
1.7 O
% O
) O
0 O
7 O
( O
0.6 O
% O
) O
2 O
( O
0.2 O
% O
) O
Venous O
14 O
( O
4.7 O
% O
) O
10 O
( O
3.4 O
% O
) O
60 O
( O
5.0 O
% O
) O
32 O
( O
3.5 O
% O
) O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
5 O
( O
1.7 O
% O
) O
3 O
( O
1.0 O
% O
) O
16 O
( O
1.3 O
% O
) O
6 O
( O
0.7 O
% O
) O
Cerebrovascular B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
* I-OSE_Labeled_AE
14 O
( O
4.7 O
% O
) O
9 O
( O
3.0 O
% O
) O
20 O
( O
1.7 O
% O
) O
17 O
( O
1.9 O
% O
) O
* O
" B-OSE_Labeled_AE
Cerebrovascular I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
" I-OSE_Labeled_AE
encompasses O
CNS B-OSE_Labeled_AE
hemorrhages I-OSE_Labeled_AE
and O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
( O
ischemic O
and O
hemorrhagic O
) O
. O

Events O
in O
this O
category O
may O
also O
be O
included O
under O
" B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O
'' O

In O
addition O
to O
the O
thrombovascular B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
edema B-OSE_Labeled_AE
occurred O
at O
a O
higher O
incidence O
in O
patients O
taking O
Aranesp O
compared O
to O
patients O
on O
placebo O
. O

Among O
all O
placebo-controlled O
studies O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
13.2 O
% O
vs O
. O
9.4 O
% O
) O
and O
edema B-OSE_Labeled_AE
( O
12.8 O
% O
vs O
. O
9.7 O
% O
) O
were O
reported O
more O
frequently O
in O
patients O
receiving O
Aranesp O
compared O
to O
the O
placebo O
group O
. O

In O
the O
SCLC B-Not_AE_Candidate
study O
the O
incidence O
of O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
10.3 O
% O
vs O
. O
3.4 O
% O
) O
and O
edema B-OSE_Labeled_AE
( O
5.6 O
% O
vs O
. O
5.1 O
% O
) O
in O
the O
Aranesp-treated O
patients O
compared O
to O
those O
receiving O
placebo O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postmarketing O
use O
of O
Aranesp O
. O

Because O
postmarketing O
reporting O
of O
adverse O
reactions O
is O
voluntary O
and O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
PRCA B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serious O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Severe O
Cutaneous B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
6.3 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

In O
clinical O
studies O
, O
the O
percentage O
of O
patients O
with O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
Aranesp I-OSE_Labeled_AE
was O
examined O
using O
the O
Biacore O
( O
r O
) O
assay O
. O

Sera O
from O
1501 O
patients O
with O
CKD B-Not_AE_Candidate
and O
1159 O
patients O
with O
cancer B-Not_AE_Candidate
were O
tested O
. O

At O
baseline O
, O
prior O
to O
Aranesp O
treatment O
, O
binding B-Not_AE_Candidate
antibodies I-Not_AE_Candidate
were I-Not_AE_Candidate
detected I-Not_AE_Candidate
in O
59 O
patients O
( O
4 O
% O
) O
with O
CKD B-Not_AE_Candidate
and O
36 O
patients O
with O
cancer B-Not_AE_Candidate
( O
3 O
% O
) O
. O

During O
Aranesp O
therapy O
( O
range O
: O
22 O
to O
177 O
weeks O
) O
, O
a O
follow-up O
sample O
was O
taken O
. O

One O
additional O
patient O
with O
CKD B-Not_AE_Candidate
and O
8 O
additional O
patients O
with O
cancer B-Not_AE_Candidate
developed O
antibodies B-OSE_Labeled_AE
capable I-OSE_Labeled_AE
of I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
Aranesp I-OSE_Labeled_AE
. O

In O
two O
studies O
of O
pediatric O
patients O
with O
CKD B-Not_AE_Candidate
aged O
2-16 O
, O
20 O
of O
111 O
patients O
with O
CKD B-Not_AE_Candidate
( O
18 O
% O
) O
receiving O
dialysis O
and O
6 O
of O
69 O
patients O
( O
9 O
% O
) O
not O
receiving O
dialysis O
had O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
ESA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
baseline O
. O

During O
therapy O
, O
4 O
additional O
patients O
receiving O
dialysis O
and O
4 O
additional O
patients O
not O
receiving O
dialysis O
developed O
antibodies B-OSE_Labeled_AE
capable I-OSE_Labeled_AE
of I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
Aranesp I-OSE_Labeled_AE
. O

None O
of O
the O
patients O
had O
antibodies B-NonOSE_AE
capable I-NonOSE_AE
of I-NonOSE_AE
neutralizing I-NonOSE_AE
the I-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
Aranesp I-NonOSE_AE
or O
endogenous O
erythropoietin O
at O
baseline O
or O
at O
end O
of O
study O
. O

No O
clinical O
sequelae O
consistent O
with O
PRCA B-NonOSE_AE
were O
associated O
with O
the O
presence B-NonOSE_AE
of I-NonOSE_AE
these O
antibodies I-NonOSE_AE
. O

The O
incidence O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
, O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
Aranesp I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
darbepoetin I-NonOSE_AE
alfa I-NonOSE_AE
that I-NonOSE_AE
cross I-NonOSE_AE
- I-NonOSE_AE
react I-NonOSE_AE
with I-NonOSE_AE
endogenous I-NonOSE_AE
erythropoietin I-NonOSE_AE
and O
other O
ESAs O
can O
result O
in O
PRCA B-NonOSE_AE
or O
severe O
anemia B-NonOSE_AE
( O
with O
or O
without O
other O
cytopenias B-NonOSE_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

